Neurology ReviewsRelapsing, progressive MS classifications should be abandonedJune 16, 2020Multiple Sclerosis
Neurology ReviewsFDA approves Uplizna for treatment of anti-AQP4 antibody–positive NMOSDJune 15, 2020Multiple Sclerosis
Neurology ReviewsCannabis misconceptions still common among MS cliniciansJune 8, 2020Multiple Sclerosis
Neurology ReviewsFunction in MS may vary significantly within EDSS scoresJune 8, 2020Multiple Sclerosis
Neurology ReviewsHerpes zoster infection with MS treatment higher in women?June 5, 2020Multiple Sclerosis
Neurology ReviewsNewest oral DMTs haven’t yet made a big impact in the MS worldJune 4, 2020Multiple Sclerosis
Neurology ReviewsConstraint-induced movement therapy may boost neuroplasticity in MSJune 3, 2020Multiple Sclerosis
Neurology ReviewsNo benefit of three commonly used medications for MS fatigueJune 1, 2020Multiple Sclerosis
Neurology ReviewsOfatumumab shows high elimination of disease activity in MSMay 29, 2020Multiple Sclerosis
Neurology ReviewsNatalizumab switch to moderate-efficacy DMT increases disability riskMay 28, 2020Multiple Sclerosis
Neurology ReviewsHigh levels of air pollution linked to increased MS riskMay 28, 2020Multiple Sclerosis
Neurology ReviewsNeurologists’ pay gets a boost, most happy with career choiceMay 22, 2020Business of MedicineMultiple SclerosisEpilepsy & Seizures
Neurology ReviewsNatalizumab bests fingolimod for relapsing-remitting MSMay 14, 2020Multiple Sclerosis
